Stocky turns companies like REDCARE PHARMACY N.V. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. SHPPF scores poorly on both growth (27.2/100) and value (3/100) fundamentals, indicating neither compelling revenue expansion nor attractive valuation relative to earnings power. Leadership alignment at 45/100 suggests meaningful misalignment between insiders and shareholders, raising governance concerns that compound the weak operational picture.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for REDCARE PHARMACY N.V.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 20/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates REDCARE PHARMACY N.V. (SHPPF) at 20/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. SHPPF scores poorly on both growth (27.2/100) and value (3/100) fundamentals, indicating neither compelling revenue expansion nor attractive valuation relative to earnings power. Leadership alignment at 45/100 suggests meaningful mis
SHPPF's current Stocky Verdict is 20/100, placing it in the "Avoid" band. This composite combines a 27/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for REDCARE PHARMACY N.V. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
REDCARE PHARMACY N.V. scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
REDCARE PHARMACY N.V.'s Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to REDCARE PHARMACY N.V..
Sign up free and unlock the full analysis on SHPPF — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for SHPPF in the app.
